Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 12/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 12/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 12/20 | 0.48 |
| ▸ | PDE5A | O76074 | 5/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
| ▸ | PDE6C | P51160 | 1/20 | 0.37 |
| ▸ | UGCG | Q16739 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2661536 | 0.93 | GABRG2 (0.49) | GABRG2GABRB3GABRA2PDE5AGABRA1 | |
| SCHEMBL4917184 | 0.91 | GABRG2 (0.47) | GABRG2GABRB3GABRA2PDE5AGABRA1 | |
| SCHEMBL2662436 | 0.91 | GABRG2 (0.49) | GABRG2GABRB3GABRA2PDE5AGABRA1 | |
| SCHEMBL2655165 | 0.90 | PDE5A (0.43) | GABRG2GABRB3GABRA2PDE5AGABRA1 | |
| SCHEMBL2661817 | 0.88 | GABRG2 (0.43) | GABRG2GABRB3GABRA2PDE5ATP53 | |
| SCHEMBL2661116 | 0.88 | GABRG2 (0.42) | GABRG2GABRB3GABRA2PDE5AGABRA1 | |
| SCHEMBL2662174 | 0.87 | GABRG2 (0.46) | GABRG2GABRB3GABRA2GABRA1GABRA5 | |
| SCHEMBL2661396 | 0.86 | PDE5A (0.43) | GABRG2GABRB3GABRA2PDE5AGABRA1 | |
| SCHEMBL2656832 | 0.86 | GABRG2 (0.49) | GABRG2GABRB3GABRA2PDE5AGABRA1 | |
| SCHEMBL2656333 | 0.86 | PDE5A (0.44) | PDE5APDE6CNPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | GABRG2 592/4885GABRB3 332/4885GABRA2 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.